Guardant Health Inc. (GH)
48.19
0.07 (0.15%)
At close: Feb 18, 2025, 3:59 PM
49.37
2.45%
After-hours: Feb 18, 2025, 04:29 PM EST
undefined% (undefined)
| Bid | 47 |
| Market Cap | 5.95B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -4.28 |
| PE Ratio (ttm) | -11.26 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 51.74 |
| Volume | 1,614,569 |
| Avg. Volume (20D) | 2,021,600 |
| Open | 49.70 |
| Previous Close | 48.12 |
| Day's Range | 47.03 - 49.90 |
| 52-Week Range | 15.81 - 50.89 |
| Beta | undefined |
About GH
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test fo...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Oct 4, 2018
Employees 1,768
Stock Exchange NASDAQ
Ticker Symbol GH
Website https://guardanthealth.com
Analyst Forecast
According to 15 analyst ratings, the average rating for GH stock is "Strong Buy." The 12-month stock price forecast is $41, which is a decrease of -14.92% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Guardant Health Inc. is scheduled to release its earnings on Feb 20, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago
+23.1%
Guardant Health shares are trading higher after th...
Unlock content with
Pro Subscription
2 months ago
+8.42%
Guardant Health shares are trading higher after a jury issued a decision in the company's favor regarding a false advertising case filed by Natera concerning statements made about Guardant's Reveal test.
